September 22, 2008
Keith A. Bostian Named President of Kemin Pharma
Charlotte Jacobs, +1-515-559-5100
Kemin Industries today named Keith A. Bostian, PhD, President of Kemin Pharma. Dr. Bostian joins Kemin from Mpex Pharmaceuticals, Inc. where he served as Chief Scientific Officer and innovator of the company's R&D platform. Dr. Bostian will add significant biopharmaceutical industry, financial and operational experience to Kemin as the Company continues to progress its clinical and preclinical programs.
"We are delighted to welcome Keith to Kemin and are confident that his impressive background across the biotech industry will be a real asset to us as we move into the next stage of development as a company," said Dr. Chris Nelson, President of Kemin Industries, Inc.. "Kemin has completed the foundation work necessary to initiate key clinical activities in the U.S. and Europe with our lead product, Anaeban(TM). Keith will be instrumental in helping Kemin move this product forward aggressively in clinical trials and will also work with our research team to advance exciting new antimicrobial and anti-inflammatory candidates from our product pipeline."
"I am thrilled to be joining Kemin at this formative stage," stated Dr. Bostian. "The need for new infectious disease therapeutic approaches is great, and Kemin Pharma's early focus on gastrointestinal disorders is compelling, given the worldwide population of individuals suffering from such diseases as acute diarrhea, antibiotic-associated diarrhea, Inflammatory Bowel Disease and Irritable Bowel Syndrome. The Kemin Pharma team has positioned the Company well to be able to offer innovative solutions to meet this need. I look forward to working with this talented group and the larger Kemin family to bring new therapeutic options to patients around the world."
As an entrepreneur-scientist, Dr. Bostian has held executive operating roles in companies financed by leading venture firms in the biotechnology arena, and has played advisory roles at the seed, pre-seed, and investment stage for numerous other organizations. Previous to Mpex he was the founder and CEO of Iconix Pharmaceuticals, Inc., a pioneer and leader in the emerging field of chemogenomics, as well as founder and COO of Microcide Pharmaceuticals, Inc., a publicly traded company with clinical and pre-clinical programs, and one of the first biotech companies formed to focus on antibiotic resistant bacteria. Previously, Dr. Bostian held senior research positions at Merck and Co., in New Jersey, USA and was a faculty member at Brown University, Division of Biology and Medicine, in Providence, RI., USA.
Dr. Bostian earned his doctorate in Biochemistry from the University of London. He has served on numerous advisory and editorial boards and is a fellow of the American Academy for Microbiology.
Kemin Pharma Bvbc, a member of the Kemin group of companies, with operations in Europe, United States and India, is a biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of infectious and inflammatory diseases. Its mission is to develop new and unique compounds for treatment, including new drugs and treatment approaches against bacteria, viruses and fungi, as well as protozoa, which present a serious, unmet medical challenge throughout the world, and for both acute and chronic gastrointestinal diseases. Its drug development pipeline includes several early clinical-stage candidates as well as an advanced-stage probiotic being launched as a dietary supplement.
The Kemin group of companies strives to improve peoples' lives of half the people in the world every day through its products and services. With over 1,000 employees worldwide, the organization operates in more than 60 countries, with manufacturing facilities in Belgium, Brazil, China, India, Singapore, South Africa, Thailand and the United States.
(c) 2008 BUSINESS WIRE. Provided by ProQuest LLC. All rights Reserved.